The booming pipeline of cell and gene therapies, and their unique requirements, means both hope for patients and potential around eligibility and coverage barriers. We talk to experts from AmerisourceBergen and TrakCel about a new partnership for these innovative treatments that can improve speed to therapy, streamline the path to care, and create a heightened level of connectivity across the supply chain.